- Home
- MGIH vs TNXP Comparison
MGIH vs TNXP Comparison
Compare MGIH & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIH
- TNXP
- Stock Information
- Founded
- MGIH 1978
- TNXP 2007
- Country
- MGIH Hong Kong
- TNXP United States
- Employees
- MGIH N/A
- TNXP N/A
- Industry
- MGIH Publishing
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- MGIH Consumer Discretionary
- TNXP Health Care
- Exchange
- MGIH Nasdaq
- TNXP Nasdaq
- Market Cap
- MGIH 18.7M
- TNXP 19.5M
- IPO Year
- MGIH 2023
- TNXP N/A
- Fundamental
- Price
- MGIH $1.43
- TNXP $0.37
- Analyst Decision
- MGIH
- TNXP Strong Buy
- Analyst Count
- MGIH 0
- TNXP 2
- Target Price
- MGIH N/A
- TNXP $53.50
- AVG Volume (30 Days)
- MGIH 20.5K
- TNXP 186.1M
- Earning Date
- MGIH 12-31-2024
- TNXP 11-12-2024
- Dividend Yield
- MGIH N/A
- TNXP N/A
- EPS Growth
- MGIH N/A
- TNXP N/A
- EPS
- MGIH N/A
- TNXP N/A
- Revenue
- MGIH $38,530,773.00
- TNXP $11,291,000.00
- Revenue This Year
- MGIH N/A
- TNXP $62.53
- Revenue Next Year
- MGIH N/A
- TNXP $26.17
- P/E Ratio
- MGIH N/A
- TNXP N/A
- Revenue Growth
- MGIH N/A
- TNXP 183.05
- 52 Week Low
- MGIH $0.93
- TNXP $0.12
- 52 Week High
- MGIH $9.57
- TNXP $21.76
- Technical
- Relative Strength Index (RSI)
- MGIH 38.05
- TNXP 62.63
- Support Level
- MGIH $1.38
- TNXP $0.18
- Resistance Level
- MGIH $1.57
- TNXP $1.30
- Average True Range (ATR)
- MGIH 0.07
- TNXP 0.11
- MACD
- MGIH -0.01
- TNXP 0.02
- Stochastic Oscillator
- MGIH 20.00
- TNXP 17.41
About MGIH Millennium Group International Holdings Limited
Millennium Group International Holdings Ltd is a paper-based packaging solutions supplier. It offers paper-based inner and outer packaging products which can be broadly categorized into packaging products and corrugated products.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.